BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.
Immunotherapy
Lymphocyte Activation
Macrophages
Translational Medical Research
Tumor Escape
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
accepted:
17
07
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
15
9
2022
Statut:
ppublish
Résumé
Cancer immunotherapy has revolutionized cancer treatment. However, considering the limited success of immunotherapy to only some cancer types and patient cohorts, there is an unmet need for developing new treatments that will result in higher response rates in patients with cancer. Immunoglobulin-like transcript 2 (ILT2), a LILRB family member, is an inhibitory receptor expressed on a variety of immune cells including T cells, natural killer (NK) cells and different myeloid cells. In the tumor microenvironment, binding of class I MHC (in particular HLA-G) to ILT2 on immune cells mediates a strong inhibitory effect, which manifests in inhibition of antitumor cytotoxicity of T and NK cells, and prevention of phagocytosis of the tumor cells by macrophages. We describe here the development and characteristics of BND-22, a novel, humanized monoclonal antibody that selectively binds to ILT2 and blocks its interaction with classical MHC I and HLA-G. BND-22 was evaluated for its binding and blocking characteristics as well as its ability to increase the antitumor activity of macrophages, T cells and NK cells in various in vitro, ex vivo and in vivo systems. Collectively, our data suggest that BND-22 enhances activity of both innate and adaptive immune cells, thus generating robust and comprehensive antitumor immunity. In humanized mice models, blocking ILT2 with BND-22 decreased the growth of human tumors, hindered metastatic spread to the lungs, and prolonged survival of the tumor-bearing mice. In addition, BND-22 improved the antitumor immune response of approved therapies such as anti-PD-1 or anti-EGFR antibodies. BND-22 is a first-in-human ILT2 blocking antibody which has demonstrated efficient antitumor activity in various preclinical models as well as a favorable safety profile. Clinical evaluation of BND-22 as a monotherapy or in combination with other therapeutics is under way in patients with cancer. NCT04717375.
Sections du résumé
BACKGROUND
Cancer immunotherapy has revolutionized cancer treatment. However, considering the limited success of immunotherapy to only some cancer types and patient cohorts, there is an unmet need for developing new treatments that will result in higher response rates in patients with cancer. Immunoglobulin-like transcript 2 (ILT2), a LILRB family member, is an inhibitory receptor expressed on a variety of immune cells including T cells, natural killer (NK) cells and different myeloid cells. In the tumor microenvironment, binding of class I MHC (in particular HLA-G) to ILT2 on immune cells mediates a strong inhibitory effect, which manifests in inhibition of antitumor cytotoxicity of T and NK cells, and prevention of phagocytosis of the tumor cells by macrophages.
METHODS
We describe here the development and characteristics of BND-22, a novel, humanized monoclonal antibody that selectively binds to ILT2 and blocks its interaction with classical MHC I and HLA-G. BND-22 was evaluated for its binding and blocking characteristics as well as its ability to increase the antitumor activity of macrophages, T cells and NK cells in various in vitro, ex vivo and in vivo systems.
RESULTS
Collectively, our data suggest that BND-22 enhances activity of both innate and adaptive immune cells, thus generating robust and comprehensive antitumor immunity. In humanized mice models, blocking ILT2 with BND-22 decreased the growth of human tumors, hindered metastatic spread to the lungs, and prolonged survival of the tumor-bearing mice. In addition, BND-22 improved the antitumor immune response of approved therapies such as anti-PD-1 or anti-EGFR antibodies.
CONCLUSIONS
BND-22 is a first-in-human ILT2 blocking antibody which has demonstrated efficient antitumor activity in various preclinical models as well as a favorable safety profile. Clinical evaluation of BND-22 as a monotherapy or in combination with other therapeutics is under way in patients with cancer.
TRIAL REGISTRATION NUMBER
NCT04717375.
Identifiants
pubmed: 36096532
pii: jitc-2022-004859
doi: 10.1136/jitc-2022-004859
pmc: PMC9472153
pii:
doi:
Substances chimiques
HLA-G Antigens
0
Banques de données
ClinicalTrials.gov
['NCT04717375']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Sci Data. 2019 Jul 24;6(1):131
pubmed: 31341169
Nat Immunol. 2018 Jan;19(1):76-84
pubmed: 29180808
J Immunol Methods. 2010 Oct 31;362(1-2):131-41
pubmed: 20858499
Clin Cancer Res. 2016 Nov 15;22(22):5461-5471
pubmed: 27169994
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
J Immunother Cancer. 2019 Jun 8;7(1):149
pubmed: 31176366
J Immunol. 2008 Aug 15;181(4):2368-81
pubmed: 18684926
Cancer Res. 2015 Dec 1;75(23):5008-13
pubmed: 26573795
Eur J Immunol. 2015 May;45(5):1560-9
pubmed: 25726929
Eur Urol. 2015 Aug;68(2):267-79
pubmed: 25824720
Eur J Immunol. 1997 Mar;27(3):660-5
pubmed: 9079806
Curr Biol. 1997 Aug 1;7(8):615-8
pubmed: 9259559
Biol Blood Marrow Transplant. 2010 May;16(5):612-21
pubmed: 20139023
Nat Rev Cancer. 2016 Jul;16(7):447-62
pubmed: 27339708
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
J Exp Med. 1997 Dec 1;186(11):1809-18
pubmed: 9382880
J Immunol. 2002 Jan 1;168(1):207-15
pubmed: 11751964
Int J Biol Sci. 2012;8(6):891-900
pubmed: 22745579
Adv Immunol. 2015;127:33-144
pubmed: 26073983
J Immunol. 1997 Mar 1;158(5):1989-93
pubmed: 9036940
Hum Reprod. 2015 Oct;30(10):2263-74
pubmed: 26307092
J Immunol. 2001 Feb 15;166(4):2514-21
pubmed: 11160312
Trends Cancer. 2021 May;7(5):389-392
pubmed: 33563576
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Cell Cycle. 2016;15(1):25-40
pubmed: 26636629
J Immunol. 2019 Aug 15;203(4):1076-1087
pubmed: 31253728
Immunity. 1997 Aug;7(2):273-82
pubmed: 9285411
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Front Immunol. 2018 Sep 27;9:2164
pubmed: 30319626
Blood. 2011 Jun 30;117(26):7021-31
pubmed: 21482709
Cancer Immunol Res. 2019 Oct;7(10):1619-1632
pubmed: 31451484
J Immunol. 2019 Dec 15;203(12):3386-3394
pubmed: 31694909
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16412-7
pubmed: 17056715
Clin Cancer Res. 2022 Jan 1;28(1):57-70
pubmed: 34598945
J Immunol. 2000 Oct 1;165(7):3742-55
pubmed: 11034379
J Clin Invest. 2011 Sep;121(9):3609-22
pubmed: 21841316
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8856-61
pubmed: 12853576
Mol Hum Reprod. 2000 Jun;6(6):535-40
pubmed: 10825371
Cell Mol Immunol. 2020 Sep;17(9):966-975
pubmed: 31273318
Immunology. 2004 Aug;112(4):531-42
pubmed: 15270723
Infect Immun. 2001 Oct;69(10):6022-9
pubmed: 11553539
J Immunol. 2005 Oct 15;175(8):5006-15
pubmed: 16210603
Immunity. 2000 Nov;13(5):727-36
pubmed: 11114384
Eur J Immunol. 1999 Jan;29(1):277-83
pubmed: 9933109
Blood. 2011 Nov 24;118(22):5840-50
pubmed: 21989990